ATE486610T1 - Anti-glypican-3-antikörper - Google Patents
Anti-glypican-3-antikörperInfo
- Publication number
- ATE486610T1 ATE486610T1 AT05760156T AT05760156T ATE486610T1 AT E486610 T1 ATE486610 T1 AT E486610T1 AT 05760156 T AT05760156 T AT 05760156T AT 05760156 T AT05760156 T AT 05760156T AT E486610 T1 ATE486610 T1 AT E486610T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- glypican
- disclosed
- antibodies
- agent
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 2
- 102000010956 Glypican Human genes 0.000 abstract 1
- 108050001154 Glypican Proteins 0.000 abstract 1
- 108050007237 Glypican-3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003966 growth inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004203637 | 2004-07-09 | ||
PCT/JP2005/013103 WO2006006693A1 (ja) | 2004-07-09 | 2005-07-08 | 抗グリピカン3抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE486610T1 true ATE486610T1 (de) | 2010-11-15 |
Family
ID=35784028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05760156T ATE486610T1 (de) | 2004-07-09 | 2005-07-08 | Anti-glypican-3-antikörper |
Country Status (26)
Country | Link |
---|---|
US (3) | US7919086B2 (de) |
EP (4) | EP2314317A3 (de) |
JP (3) | JP4011100B2 (de) |
KR (2) | KR101300545B1 (de) |
CN (4) | CN105820249A (de) |
AT (1) | ATE486610T1 (de) |
AU (1) | AU2005256113B2 (de) |
BR (1) | BRPI0506125B8 (de) |
CA (1) | CA2544692C (de) |
CY (1) | CY1111649T1 (de) |
DE (1) | DE602005024502D1 (de) |
DK (1) | DK1674111T3 (de) |
ES (1) | ES2353967T3 (de) |
HK (1) | HK1092161A1 (de) |
IL (1) | IL172938A (de) |
MX (1) | MXPA06002890A (de) |
MY (1) | MY145073A (de) |
NO (1) | NO343105B1 (de) |
NZ (2) | NZ545720A (de) |
PL (1) | PL1674111T3 (de) |
PT (1) | PT1674111E (de) |
RU (2) | RU2427588C2 (de) |
SI (1) | SI1674111T1 (de) |
TW (1) | TWI455946B (de) |
UA (1) | UA94019C2 (de) |
WO (1) | WO2006006693A1 (de) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
MY145073A (en) * | 2004-07-09 | 2011-12-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
JP4733042B2 (ja) | 2004-08-24 | 2011-07-27 | 中外製薬株式会社 | 抗グリピカン3抗体を用いたアジュバント療法 |
NZ554940A (en) * | 2004-10-26 | 2010-04-30 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody having modified sugar chain |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
WO2007082352A1 (en) * | 2006-01-20 | 2007-07-26 | Child Health Research Institute Inc | Method of treatment, prophylaxis and diagnosis of pathologies of the bone |
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
EP3345616A1 (de) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper |
AU2007239679B2 (en) * | 2006-04-13 | 2012-10-11 | Chugai Seiyaku Kabushiki Kaisha | Taurine transporter gene |
US20100233759A1 (en) | 2007-03-15 | 2010-09-16 | Chugai Seiyaku Kabushiki Kaisha | Method for production of polypeptide |
DK2154244T3 (en) | 2007-04-26 | 2017-06-12 | Chugai Pharmaceutical Co Ltd | CELL CULTIVATION PROCEDURE WHEN AN ACID-ENRICHED MEDIUM IS USED |
RS54624B1 (en) * | 2007-07-17 | 2016-08-31 | E. R. Squibb & Sons, L.L.C. | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 |
MX2010001319A (es) | 2007-08-07 | 2010-06-01 | Chugai Pharmaceutical Co Ltd | Metodo para producir proteinas heterogeneas. |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
AR066172A1 (es) * | 2007-09-28 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica. |
DK2202307T4 (da) * | 2007-10-15 | 2021-10-04 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstiling af et antistof |
EP2194126B1 (de) | 2007-10-15 | 2014-01-15 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur konstruktion von zellen mit hoher produktivität von fremdprotein |
JP5337044B2 (ja) | 2007-10-24 | 2013-11-06 | 中外製薬株式会社 | 異種タンパク質製造のための細胞及びそれを用いた製造方法 |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
EP2262837A4 (de) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1-bindende proteine |
KR20110005812A (ko) | 2008-03-17 | 2011-01-19 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법 |
CL2009000647A1 (es) | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
PT2315777T (pt) | 2008-07-08 | 2017-07-25 | Geneuro Sa | Uso terapêutico de ligandos específicos nas doenças associadas a msrv |
WO2010050448A1 (ja) | 2008-10-28 | 2010-05-06 | 中外製薬株式会社 | ペプチド含有動物細胞培養用培地 |
SG177252A1 (en) | 2008-12-01 | 2012-03-29 | Lab Corp America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
SG172984A1 (en) * | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-2 expression |
SG172983A1 (en) * | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
WO2010123014A1 (ja) | 2009-04-22 | 2010-10-28 | 中外製薬株式会社 | 異種タンパク質を高生産する細胞の作製方法 |
FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
KR101787118B1 (ko) * | 2009-08-07 | 2017-10-18 | 교와 핫꼬 기린 가부시키가이샤 | 항아밀로이드β 올리고머 인간화 항체 |
JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
JP6097690B2 (ja) | 2010-09-02 | 2017-03-15 | ヴァクシネックス, インコーポレイテッド | 抗cxcl13抗体およびそれを用いる方法 |
RU2642318C2 (ru) | 2010-11-30 | 2018-01-24 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
BR112013013311A2 (pt) * | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
BR112013018751B1 (pt) * | 2010-12-28 | 2021-01-05 | Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.) | método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo |
CN102180969B (zh) * | 2011-01-30 | 2013-04-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗肝癌活性单克隆抗体及其应用 |
AU2012233313C1 (en) | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
TWI647309B (zh) | 2011-04-01 | 2019-01-11 | 中外製藥股份有限公司 | 重組多肽之製造方法 |
CN105968209B (zh) * | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
AR087364A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
CN110680920A (zh) | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | 诱导针对靶抗原的免疫应答的抗原结合分子 |
US20140335089A1 (en) | 2011-09-30 | 2014-11-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
EP2765192A4 (de) | 2011-10-05 | 2015-04-15 | Chugai Pharmaceutical Co Ltd | Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne |
US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
ES2873035T3 (es) * | 2012-01-31 | 2021-11-03 | Sbi Biotech Co Ltd | Anticuerpo antifosfolipasa D4 |
AU2013223087B2 (en) | 2012-02-24 | 2018-02-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via FcgammaRIIb |
AU2013225812B2 (en) | 2012-03-02 | 2017-11-30 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
TWI797443B (zh) | 2012-05-30 | 2023-04-01 | 日商中外製藥股份有限公司 | 抗原結合分子之篩選或製造方法 |
WO2013181543A1 (en) * | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
WO2014058025A1 (ja) | 2012-10-10 | 2014-04-17 | 中外製薬株式会社 | 改変宿主細胞の樹立方法 |
CN103833852A (zh) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
EP3557260B1 (de) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-gerichtetes arzneimittel, das einem patienten verabreicht wird, der auf die gpc3-gerichtete arzneimitteltherapie reagiert |
NZ710744A (en) | 2013-01-31 | 2020-07-31 | Vaccinex Inc | Methods for increasing immunoglobulin a levels |
WO2014159087A1 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma |
CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
TWI702316B (zh) | 2013-12-04 | 2020-08-21 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
CN105849562B (zh) | 2013-12-24 | 2019-08-16 | 中外制药株式会社 | 可溶性gpc3蛋白质的测定方法 |
MX2016012552A (es) | 2014-04-07 | 2017-01-09 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
JP6827319B2 (ja) * | 2014-05-08 | 2021-02-10 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
BR112016026299A2 (pt) | 2014-05-13 | 2018-02-20 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão |
WO2015172341A1 (zh) * | 2014-05-14 | 2015-11-19 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
JP6858559B2 (ja) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | 蛋白質溶液の粘度測定方法 |
US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
AP2017009758A0 (en) * | 2014-09-16 | 2017-02-28 | Ovascience Inc | Anti-vasa antibodies, and methods of production and use thereof |
US20160082129A1 (en) * | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
WO2016070001A1 (en) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
WO2016112423A1 (en) * | 2015-01-16 | 2016-07-21 | Minomic International Ltd. | Glypican epitopes and uses thereof |
CN104610441B (zh) * | 2015-03-04 | 2018-02-13 | 首都医科大学 | 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
JP7096667B2 (ja) | 2015-07-01 | 2022-07-06 | 中外製薬株式会社 | Gpc3標的治療剤が有効である患者に投与されるgpc3標的治療剤 |
CA2994751A1 (en) * | 2015-08-03 | 2017-02-09 | Carsgen Therapeutics, Ltd | Antibody against glypican-3 and application thereof |
CN105112046A (zh) * | 2015-09-29 | 2015-12-02 | 南通大学 | 核壳结构量子点的制备方法、靶向肿瘤标志物gpc-3的荧光纳米探针及其制备方法 |
CN105126123B (zh) * | 2015-09-29 | 2018-04-03 | 南通大学 | 纳米探针的制备方法、基于天然产物单体和纳米探针的纳米药物的制备方法及应用 |
KR101796688B1 (ko) * | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
EP3378488A4 (de) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur verbesserung der humoralen immunreaktion |
BR112018009312A8 (pt) | 2015-12-28 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | método para promover eficiência de purificação de polipeptídeo contendo região de fc |
JP6292564B2 (ja) * | 2016-03-10 | 2018-03-14 | シスメックス株式会社 | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット |
TW202214700A (zh) | 2016-03-14 | 2022-04-16 | 日商中外製藥股份有限公司 | 用於癌之治療的細胞傷害誘導治療劑 |
US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
WO2017168726A1 (ja) * | 2016-03-31 | 2017-10-05 | 国立大学法人東北大学 | がん微小環境を標的とした抗ポドカリキシン抗体 |
ES2937699T3 (es) | 2016-04-22 | 2023-03-30 | Crage Medical Co Ltd | Composiciones y métodos de inmunoterapia celular |
CN110035768A (zh) | 2016-07-26 | 2019-07-19 | 泰莎治疗私人有限公司 | 嵌合抗原受体 |
WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
JP2018093823A (ja) | 2016-12-15 | 2018-06-21 | Heartseed株式会社 | 未分化幹細胞除去剤及び未分化幹細胞除去方法 |
EP3565596A4 (de) | 2017-01-05 | 2020-12-16 | Brown University | Verfahren und zusammensetzungen in verbindung mit anti-chi3l1-antikörperreagenzien |
BR112019013947A2 (pt) | 2017-01-10 | 2020-02-11 | Yamaguchi University | Anticorpo, receptor de antígeno quimérico, célula imunocompetente, gene de anticorpo, vetor, célula hospedeira, método para detectar gpc3, e, kit para a detecção de gpc3. |
US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
EP3615574A4 (de) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | Spezifisch glypican 3 erkennende konstrukte und deren verwendung |
EP3643725A4 (de) * | 2017-06-20 | 2021-03-17 | Savid Therapeutics Inc. | Antisulfatierter glycosaminoglycan-antikörper |
EP3658185A4 (de) | 2017-07-28 | 2021-07-14 | Phanes Therapeutics, Inc. | Anti-tim-3-antikörper und verwendungen davon |
US10766968B2 (en) | 2017-08-23 | 2020-09-08 | Brown University | Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
SG11202004627WA (en) | 2017-11-28 | 2020-06-29 | Chugai Pharmaceutical Co Ltd | Ligand-binding molecule having adjustable ligand-binding activity |
AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
JPWO2019225568A1 (ja) | 2018-05-21 | 2021-07-01 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
WO2019230725A1 (ja) | 2018-05-28 | 2019-12-05 | 中外製薬株式会社 | 充填ノズル |
EP3816182A4 (de) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | Ligandbindungsmolekül mit einzeldomänen-antikörper |
EP3825404A4 (de) | 2018-07-17 | 2022-04-13 | Noile-Immune Biotech, Inc. | Einkettiger anti-gpc3-antikörper mit car |
CN110760005A (zh) * | 2018-07-25 | 2020-02-07 | 上海细胞治疗集团有限公司 | 一种靶向Glypican-3抗原的嵌合抗原受体修饰T细胞及其用途 |
BR112021006254A2 (pt) | 2018-10-01 | 2021-07-27 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos |
EP3870598A1 (de) | 2018-10-23 | 2021-09-01 | Dragonfly Therapeutics, Inc. | Heterodimere fc-kondensierte proteine |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
EP3941942A4 (de) * | 2019-03-21 | 2023-04-26 | Agency For Science, Technology And Research | Zusammensetzung |
WO2020230901A1 (ja) | 2019-05-15 | 2020-11-19 | 協和キリン株式会社 | Cd40とgpc3に結合するバイスペシフィック抗体 |
EP3981428A4 (de) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | Proteasesubstrat und polypeptid mit proteasespaltungssequenz |
AU2020288499A1 (en) | 2019-06-05 | 2022-01-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody cleavage site-binding molecule |
WO2021010346A1 (ja) * | 2019-07-12 | 2021-01-21 | 国立大学法人京都大学 | 歯の再生治療のためのusag-1を標的分子とした中和抗体 |
AU2020319874A1 (en) * | 2019-08-01 | 2022-03-17 | R.P. Scherer Technologies, Llc | Antibody specific for GPC3 and methods of use thereof |
CN112390886B (zh) * | 2019-08-16 | 2022-08-16 | 原启生物科技(上海)有限责任公司 | 一种分离的抗原结合蛋白及其用途 |
WO2021110095A1 (zh) * | 2019-12-05 | 2021-06-10 | 上海翰森生物医药科技有限公司 | 抗gpc3抗体、其抗原结合片段及其医药用途 |
CN111116749B (zh) * | 2019-12-31 | 2023-02-17 | 南京拂晓生物科技有限公司 | 重组的人源化gpc3抗体及其制备和应用 |
CN116096353A (zh) | 2020-04-22 | 2023-05-09 | 蜻蜓疗法股份有限公司 | 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺 |
CN111909902B (zh) * | 2020-06-24 | 2021-12-21 | 天津金虹生物科技开发有限公司 | 一种杂交瘤细胞株、单克隆抗体及其制备方法和应用、制备致敏胶乳原液的方法以及试剂盒 |
BR112023000537A2 (pt) | 2020-07-31 | 2023-01-31 | Chugai Pharmaceutical Co Ltd | Composições farmacêuticas incluindo célula que expressa o receptor quimérico |
AU2021343594A1 (en) | 2020-09-17 | 2023-05-11 | Shanghai Lyn-Crest Enterprise Management Co., Ltd. | Bispecific recombinant protein and use thereof |
CN114478780A (zh) * | 2020-10-23 | 2022-05-13 | 华中农业大学 | 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用 |
CN114478788A (zh) | 2020-11-11 | 2022-05-13 | 高新 | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 |
KR20220080381A (ko) * | 2020-12-07 | 2022-06-14 | (주)이노베이션바이오 | Gpc3에 특이적인 항체 및 이의 용도 |
AU2021399955A1 (en) | 2020-12-18 | 2023-08-03 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
CN112608907B (zh) * | 2020-12-18 | 2023-01-17 | 十堰市太和医院(湖北医药学院附属医院) | 磷脂酰肌醇蛋白聚糖3单克隆抗体,杂交瘤细胞株和应用 |
EP4274853A1 (de) * | 2021-01-05 | 2023-11-15 | National Institute Of Biological Sciences, Beijing | Bispezifischer antikörper gegen gpc3 und cd47 |
WO2022166876A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏先声药业有限公司 | 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用 |
MX2023010916A (es) | 2021-03-17 | 2023-12-14 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas. |
EP4333892A1 (de) * | 2021-05-07 | 2024-03-13 | Senti Biosciences, Inc. | Chimäre antigenrezeptoren und verfahren zur verwendung |
WO2022268196A1 (zh) * | 2021-06-25 | 2022-12-29 | 天辰生物医药(苏州)有限公司 | 靶向gpc3的抗原结合蛋白 |
CN113248616B (zh) * | 2021-07-07 | 2022-04-12 | 北京艺妙神州医药科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
WO2023283361A1 (en) * | 2021-07-07 | 2023-01-12 | Triumvira Immunologics Usa, Inc. | Gpc3 t cell-antigen couplers and uses thereof |
CN113354737B (zh) * | 2021-07-20 | 2022-11-18 | 广州爱思迈生物医药科技有限公司 | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 |
CA3228311A1 (en) | 2021-08-12 | 2023-02-16 | Ke HE | Bispecific recombinant protein and use thereof |
TW202317638A (zh) * | 2021-08-30 | 2023-05-01 | 台灣浩鼎生技股份有限公司 | 雙特異性樹突狀細胞接合體及其用途 |
CN117897410A (zh) * | 2021-09-06 | 2024-04-16 | 南京传奇生物科技有限公司 | 抗gpc3嵌合抗原受体及其使用方法 |
KR20240082388A (ko) | 2021-10-08 | 2024-06-10 | 추가이 세이야쿠 가부시키가이샤 | 프리필드 시린지 제제의 조제 방법 |
KR20230060546A (ko) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
KR20240103006A (ko) | 2021-11-16 | 2024-07-03 | 소티오 바이오테크 인크. | 점액성/원형 세포 지방육종 환자의 치료 |
WO2023092099A1 (en) * | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2024076375A1 (en) * | 2022-10-07 | 2024-04-11 | Jecho Laboratories, Inc. | Glypican 3 antibody and related methods |
CN116444653B (zh) * | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 |
CN116333172B (zh) * | 2023-05-04 | 2024-02-09 | 广州百暨基因科技有限公司 | 融合蛋白及其应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPH0242355A (ja) | 1988-08-02 | 1990-02-13 | Hitachi Constr Mach Co Ltd | 超音波検査装置 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0546073B1 (de) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
JPH04336051A (ja) | 1991-05-10 | 1992-11-24 | Toshiba Corp | 超音波診断装置 |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU4116793A (en) * | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
EP0770628B9 (de) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
WO1996004925A1 (en) * | 1994-08-12 | 1996-02-22 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
CN100335501C (zh) | 1996-09-26 | 2007-09-05 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6617156B1 (en) * | 1997-08-15 | 2003-09-09 | Lynn A. Doucette-Stamm | Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
CN1277632A (zh) * | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
JPH11118775A (ja) | 1997-10-09 | 1999-04-30 | Canon Inc | 超音波検査装置 |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
EP2261229A3 (de) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glykosylierungs-Engineering von Antikörpern zur Verbesserung der antikörperabhängigen zellvermittelten Zytotoxizität |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA01008110A (es) * | 1999-02-12 | 2002-10-23 | Scripps Research Inst | Metodos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias anti-angiogenicas e inmunoterapia. |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP3606132B2 (ja) | 1999-10-14 | 2005-01-05 | Jfeエンジニアリング株式会社 | 超音波探傷方法およびその装置 |
JP2002048867A (ja) | 2000-08-07 | 2002-02-15 | Mitsubishi Heavy Ind Ltd | 音響探査装置 |
WO2002022739A1 (en) | 2000-09-12 | 2002-03-21 | Union Carbide Chemicals & Plastics | Polymer composites containing alkylene oxide copolymers |
EP3690043A1 (de) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antikörperzusammensetzungsproduzierendes zelle |
JP4336051B2 (ja) | 2001-01-31 | 2009-09-30 | 株式会社エヌ・ティ・ティ・ドコモ | 無線通信端末、発呼制限方法及びプログラム |
EP1383800A4 (de) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | ZUSAMMEN MIT GnTIII EXPRIMIERTE REKOMBINANTE ANTIKÖRPER |
US20020194747A1 (en) * | 2001-06-21 | 2002-12-26 | Passke Joel L. | Footwear with bladder filter |
CA2451493C (en) * | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
EP1423510A4 (de) * | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Antikörperglykosylierungsvarianten mit erhöhter antikörperabhängiger zellulärer zytotoxizität |
JP4087098B2 (ja) | 2001-11-14 | 2008-05-14 | 株式会社東芝 | 超音波検査装置 |
JP3961359B2 (ja) | 2002-07-18 | 2007-08-22 | 株式会社東芝 | 超音波画像化装置 |
WO2003042686A1 (fr) | 2001-11-14 | 2003-05-22 | Kabushiki Kaisha Toshiba | Echographe, transducteur ultrasons, instrument d'examen et dispositif d'ultrasonographie |
EP1464702A4 (de) | 2001-12-28 | 2005-09-21 | Chugai Pharmaceutical Co Ltd | Verfahren zur proteinstabilisierung |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
WO2003100429A2 (en) * | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
TW200413406A (en) | 2002-08-26 | 2004-08-01 | Kirin Brewery | Peptides and drugs containing the same |
WO2004023145A1 (ja) * | 2002-09-04 | 2004-03-18 | Perseus Proteomics Inc. | Gpc3の検出による癌の診断方法 |
AU2002328429A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
JP4090345B2 (ja) | 2002-12-24 | 2008-05-28 | 株式会社グラノプト | 液相結晶成長法 |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
EP1671645A4 (de) | 2003-09-04 | 2007-07-25 | Chugai Pharmaceutical Co Ltd | Heilmittel und mittel zum nachweis von gallengangskrebs |
ITBO20040008U1 (it) | 2004-02-03 | 2004-05-03 | Tonazzi S R L | Macchina per il riempimento e la chiusura di tubetti |
MY145073A (en) | 2004-07-09 | 2011-12-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
WO2006023420A2 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
JP4733042B2 (ja) * | 2004-08-24 | 2011-07-27 | 中外製薬株式会社 | 抗グリピカン3抗体を用いたアジュバント療法 |
NZ554940A (en) * | 2004-10-26 | 2010-04-30 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody having modified sugar chain |
EP1829961A4 (de) * | 2004-12-22 | 2008-06-04 | Chugai Pharmaceutical Co Ltd | Verfahren zur herstellung eines antikörpers unter verwendung einer zelle mit gehemmter fucosetransporterfunktion |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
WO2007137170A2 (en) * | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
KR20110005812A (ko) * | 2008-03-17 | 2011-01-19 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법 |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
-
2005
- 2005-07-08 MY MYPI20053148A patent/MY145073A/en unknown
- 2005-07-08 US US10/583,795 patent/US7919086B2/en active Active
- 2005-07-08 MX MXPA06002890A patent/MXPA06002890A/es active IP Right Grant
- 2005-07-08 RU RU2006104842/10A patent/RU2427588C2/ru active
- 2005-07-08 CN CN201610183223.5A patent/CN105820249A/zh active Pending
- 2005-07-08 ES ES05760156T patent/ES2353967T3/es active Active
- 2005-07-08 EP EP10011845A patent/EP2314317A3/de not_active Withdrawn
- 2005-07-08 NZ NZ545720A patent/NZ545720A/en unknown
- 2005-07-08 CN CN2005800008074A patent/CN1842540B/zh active Active
- 2005-07-08 EP EP05760156A patent/EP1674111B1/de active Active
- 2005-07-08 CN CN202010826784.9A patent/CN111925445A/zh active Pending
- 2005-07-08 BR BRPI0506125A patent/BRPI0506125B8/pt active IP Right Grant
- 2005-07-08 NZ NZ579543A patent/NZ579543A/en unknown
- 2005-07-08 UA UAA200602628A patent/UA94019C2/ru unknown
- 2005-07-08 AT AT05760156T patent/ATE486610T1/de active
- 2005-07-08 PT PT05760156T patent/PT1674111E/pt unknown
- 2005-07-08 AU AU2005256113A patent/AU2005256113B2/en active Active
- 2005-07-08 KR KR1020067004261A patent/KR101300545B1/ko active IP Right Grant
- 2005-07-08 CA CA2544692A patent/CA2544692C/en active Active
- 2005-07-08 EP EP15153329.6A patent/EP2898897A3/de not_active Withdrawn
- 2005-07-08 DE DE602005024502T patent/DE602005024502D1/de active Active
- 2005-07-08 WO PCT/JP2005/013103 patent/WO2006006693A1/ja not_active Application Discontinuation
- 2005-07-08 SI SI200531212T patent/SI1674111T1/sl unknown
- 2005-07-08 PL PL05760156T patent/PL1674111T3/pl unknown
- 2005-07-08 CN CN2012101528190A patent/CN102702353A/zh active Pending
- 2005-07-08 DK DK05760156.9T patent/DK1674111T3/da active
- 2005-07-08 KR KR1020137001503A patent/KR101413402B1/ko active IP Right Grant
- 2005-07-08 JP JP2006524550A patent/JP4011100B2/ja active Active
- 2005-07-08 EP EP10003424.8A patent/EP2216046B1/de not_active Not-in-force
- 2005-07-11 TW TW094123428A patent/TWI455946B/zh active
-
2006
- 2006-01-02 IL IL172938A patent/IL172938A/en active IP Right Grant
- 2006-08-03 NO NO20063539A patent/NO343105B1/no unknown
- 2006-11-17 HK HK06112685.9A patent/HK1092161A1/xx unknown
-
2009
- 2009-05-08 JP JP2009113159A patent/JP2009232848A/ja active Pending
-
2010
- 2010-06-09 US US12/797,349 patent/US20100248359A1/en not_active Abandoned
-
2011
- 2011-02-03 CY CY20111100122T patent/CY1111649T1/el unknown
- 2011-04-21 RU RU2011115845A patent/RU2611751C2/ru active
-
2012
- 2012-09-10 JP JP2012198364A patent/JP5715603B2/ja active Active
-
2015
- 2015-05-15 US US14/713,416 patent/US20150259417A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE486610T1 (de) | Anti-glypican-3-antikörper | |
ATE516842T1 (de) | Intravasculärer führungsdraht | |
HUS1700028I1 (hu) | Antitestek a Clostridium difficile toxinok ellen és azok felhasználásai | |
RS53984B1 (en) | IP-10 ANTIBODIES AND THEIR USES | |
WO2005113000A3 (en) | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody | |
SV2007002227A (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 | |
TW200700081A (en) | Anti-ctla-4 antibody compositions | |
WO2007120334A3 (en) | Methods and compositions for targeting polyubiquitin | |
WO2006086208A3 (en) | 5-fluoro-uracil immunoassay | |
EP2000541A4 (de) | Humanisierter monoklonaler anti-cd20-antikörper | |
WO2006102200A3 (en) | Docetaxel immunoassay | |
DE60235588D1 (de) | Monoklonales Antikörper gegen das HCV Kernantigen | |
BRPI0407680A (pt) | métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas | |
WO2006015098A3 (en) | Taxol immunoassay | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
WO2006020263A3 (en) | Cytoxan antibodies and immunoassay | |
WO2007002096A3 (en) | Methods and compositions for targeting ifnar2 | |
UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его | |
TR201900355T4 (tr) | Anti-ctla-4 antikor kompozisyonları. | |
UA93875C2 (ru) | Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1674111 Country of ref document: EP |